A phase-3 study of DYNE-101 in Myotonic-dystrophy (DM1)
Latest Information Update: 15 May 2025
At a glance
- Drugs DYNE-101 (Primary)
- Indications Myotonic dystrophy
- Focus Registrational; Therapeutic Use
Most Recent Events
- 15 May 2025 New trial record
- 08 May 2025 According to a Dyne Therapeutics media release, the company continues to advance preparations for a Phase 3 trial with the goal of initiating the trial in 2025.